G1 Therapeutics' PRESERVE 2 Phase 3 Trial Of Trilaciclib Before First Line Chemotherapy in Metastatic Triple Negative Breast Cancer Did Not Achieve Statistical Significance In Primary Endpoint of Overall Survival
Portfolio Pulse from Benzinga Newsdesk
G1 Therapeutics' Phase 3 trial of Trilaciclib in metastatic triple-negative breast cancer did not achieve statistical significance in overall survival. The company will now focus on the extensive-stage small cell lung cancer market and is sufficiently funded to achieve anticipated profitability by the second half of 2025.
June 24, 2024 | 10:34 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
G1 Therapeutics' Phase 3 trial of Trilaciclib in metastatic triple-negative breast cancer did not achieve statistical significance in overall survival. The company will now focus on the extensive-stage small cell lung cancer market and is sufficiently funded to achieve anticipated profitability by the second half of 2025.
The failure to achieve statistical significance in the primary endpoint of overall survival in the Phase 3 trial is a negative development for G1 Therapeutics. However, the company's shift in focus to the ES-SCLC market and its sufficient funding to achieve profitability by the second half of 2025 provide some positive outlook. Overall, the immediate impact on the stock price is likely to be negative due to the trial results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100